Akari Therapeutics, Plc
NASDAQ: AKTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Abizer Gaslightwala
- Employees
- 8
- Headquarters
- London, United Kingdom
- IPO year
- 2014
- Market cap
- $12.3M
- Website
- https://www.akaritx.com
Loading AKTX…
Loading profile data…Frequently asked questions about AKTX
What does Akari Therapeutics, Plc (AKTX) do?
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nom...
Where does AKTX trade?
Akari Therapeutics, Plc (AKTX) trades on the NASDAQ Capital Market.
What sector is AKTX in?
Akari Therapeutics, Plc (AKTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Akari Therapeutics, Plc?
Abizer Gaslightwala is the chief executive officer of Akari Therapeutics, Plc (AKTX).
Where is Akari Therapeutics, Plc headquartered?
Akari Therapeutics, Plc is headquartered in United Kingdom.
Does AKTX pay a dividend?
Akari Therapeutics, Plc (AKTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AKTX go public?
Akari Therapeutics, Plc (AKTX) completed its initial public offering in 2014.
Is AKTX an ADR?
Yes — AKTX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Akari Therapeutics, Plc reporting and dividends follow the underlying issuer.